What are the approved forms and inhaler options for using Breo Ellipta in the U.S.?
According to available sources, Breo Ellipta is approved in the U.S. as a dry powder inhaler (DPI) that delivers a fixed combination of fluticasone furoate and vilanterol for once-daily use in managing asthma and COPD.
Overview
If you’re considering Breo Ellipta for asthma or chronic obstructive pulmonary disease (COPD), it’s useful to understand the delivery method and formulation. This helps patients and caregivers make informed decisions about inhaler use and treatment routines.
- Breo Ellipta comes in pre-dosed dry powder inhaler forms
- The device is used once daily and combines two active ingredients
- Indicated for long-term maintenance therapy, not rescue treatment
Let’s look at how it works and what conditions it’s designed to treat.
Detailed Information
How it works
Breo Ellipta may work by relaxing airway muscles and reducing inflammation in the lungs.
Its combination of fluticasone furoate (a corticosteroid) and vilanterol (a long-acting beta2-agonist) allows for improved airflow and reduced inflammation when used consistently. The Ellipta device releases a specific dose of powder medication through inhalation once a day.
Clinical applications
According to Drugs.com, Breo Ellipta is used as a maintenance inhaler to help control symptoms associated with asthma and COPD. It is not meant for sudden breathing problems or emergencies.
It is generally prescribed for adults with COPD and for patients aged 18 and older with asthma who need both an anti-inflammatory and bronchodilator therapy.
Safety and Effectiveness
Safety profile
Common side effects may include headache, respiratory infections, throat irritation, and hoarseness. Serious but less common effects can include increased risk of pneumonia in COPD patients and potential for adrenal suppression when used long-term.
For official safety details, refer to this patient document from Israel’s Ministry of Health.
FDA approval and indications
Breo Ellipta is FDA-approved in the U.S. for once-daily treatment of asthma (in patients 18+) and COPD. The approval is based on its combination of a corticosteroid and a beta2-agonist proven to support daily maintenance respiratory care.
Always consult a healthcare provider to ensure it’s appropriate for your individual condition and treatment goals.
Access and Availability
How to obtain safely
Breo Ellipta requires a prescription and must be obtained from a licensed pharmacy. Online services like IsraelPharm offer legitimate access with a valid prescription.
Your healthcare provider will help determine the proper strength and ensure it’s compatible with your medical history and needs.
Key Takeaways
- Breo Ellipta is a dry powder inhaler approved for once-daily asthma and COPD treatment
- It combines fluticasone furoate (steroid) and vilanterol (bronchodilator)
- FDA-approved for adults with asthma and for COPD treatment
- Must be used regularly, not for acute symptom relief
- Available via prescription from licensed providers and pharmacies
FAQ
Can I use Breo Ellipta every day?
Yes, Breo Ellipta is designed for once-daily use. It should be taken at the same time each day for consistent effect, as recommended by your provider.
Does Breo Ellipta come in different doses?
Yes, Breo Ellipta is available in multiple strengths to suit different treatment needs, including 100/25 mcg and 200/25 mcg doses. Your provider will choose the strength appropriate for your condition.
Is Breo Ellipta meant for sudden breathing problems?
No, this inhaler is not a rescue medication. It is intended for long-term control and should not be used for immediate relief of acute symptoms.
How do I know if this inhaler is right for me?
Your healthcare provider will assess your lung function, symptoms, and treatment history to determine if Breo Ellipta is appropriate for you.
Where can I get Breo Ellipta at a reliable price?
You can obtain Breo Ellipta from licensed pharmacies like IsraelPharm, which offers safe delivery options with a valid prescription.
